Hannah Clarke

Associate Editor at MJH Life Sciences

Editor, MJH Life Sciences | MPH candidate at Johns Hopkins University | views expressed are my own

Featured in: Favicon

mjhlifesciences.com Favicon

pharmaceutical-journal.com Favicon

cancernetwork.com Favicon

curetoday.com Favicon

onclive.com Favicon

managedhealthcareexecutive.com Favicon

targetedonc.com Favicon

urologytimes.com Favicon

oncnursingnews.com

Articles

Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

2 weeks ago | urologytimes.com | Hannah Clarke

Second-line cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) demonstrated efficacy and manageable safety in patients with advanced renal cell carcinoma (RCC) regardless of the prior immunotherapy-based combination used in the first-line setting, according to data from a subgroup analysis of the phase 3 CONTACT-03 trial (NCT04338269).1The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Phase 1 study launches of novel CYP11A1 inhibitor for mCRPC

2 weeks ago | urologytimes.com | Hannah Clarke

The first patient has been dosed in a phase 1 trial (NCT06801236) investigating the novel CYP11A1 inhibitor ACE-232 in patients with metastatic castration-resistant prostate cancer (mCRPC), Acerand Therapeutics announced in a news release.1 According to the company, ACE-232 is a “highly potent and selective small-molecule inhibitor of CYP11A1, a key adrenal enzyme involved in the first and rate-limiting step of steroid hormone biosynthesis.” In preclinical studies, ACE-232 demonstrated...
FDA authorizes Expanded Access Program of Anktiva for lymphopenia

3 weeks ago | urologytimes.com | Hannah Clarke

The FDA has authorized an Expanded Access Program (NCT06956547) for use of nogapendekin alfa inbakicept-pmln (NAI; Anktiva) to manage lymphopenia in adult patients with refractory or relapsed solid tumors, including genitourinary tumors, who have progressed after first-line standard-of-care treatment with chemotherapy, radiation, and/or checkpoint inhibitors, ImmunityBio announced in a news release.1 The Expanded Access Program is specifically assessing the use of ImmunityBio’s Cancer...
Perioperative Sacituzumab Govitecan Plus Pembrolizumab Is Safe, Active in MIBC

3 weeks ago | onclive.com | Hannah Clarke

Perioperative treatment with the combination of sacituzumab govitecan-hziy (Trodelvy) and pembrolizumab (Keytruda) produced complete responses (CRs) with a manageable safety profile in patients with muscle-invasive bladder cancer (MIBC), according to interim findings from the phase 2 SURE-02 trial (NCT05535218) presented at the 2025 ASCO Annual Meeting.
Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

3 weeks ago | urologytimes.com | Hannah Clarke

The target enrollment has been met in the pivotal #HOPE4KIDNEY trial (NCT05820087), evaluating the safety and effectiveness of the Edison System in destroying primary solid renal tumors via the histotripsy procedure, HistoSonics announced in a news release.1 According to the company, the Edison Histotripsy System is “the first and only platform to use histotripsy, a non-thermal, non-invasive focused ultrasound technology, to mechanically liquefy tumors without surgery, radiation, or systemic...
Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

3 weeks ago | urologytimes.com | Hannah Clarke

China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) seeking approval of sintilimab (Tyvyt) plus fruquintinib (Elunate) for patients with locally advanced or metastatic renal cell carcinoma (RCC) who have failed prior treatment with 1 tyrosine kinase inhibitor (TKI), Innovent and HUTCHMED announced in a joint news release.1 "Kidney cancer continues to pose significant challenges in China, with limited treatment options for patients who fail...
Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

3 weeks ago | urologytimes.com | Hannah Clarke

Treatment with BCG plus mitomycin demonstrated comparable efficacy and safety to BCG alone while leading to fewer treatment discontinuations and fewer BCG doses in patients with non–muscle invasive bladder cancer (NMIBC), according to data from the phase 3 ANZUP 1301 trial (NCT02948543) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.1 According to presenting author Professor Dickon Hayne, these findings have important implications in the...
Zanzalintinib plus nivolumab shows promising clinical activity in ccRCC

3 weeks ago | urologytimes.com | Hannah Clarke

First-line zanzalintinib in combination with nivolumab demonstrated encouraging preliminary activity with acceptable tolerability in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC), according to data from the phase 1b STELLAR-002 trial (NCT05176483) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.1 Data also showed that the addition of relatlimab to the doublet regimen did not appear to confer a benefit in...
Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

3 weeks ago | urologytimes.com | Hannah Clarke

Data from the phase 3 AMPLITUDE trial (NCT04497844) showed that adding niraparib (Zejula) to abiraterone acetate (Zytiga) plus prednisone (AAP) led to a statistically significant improvement in radiographic progression-free survival (rPFS) vs placebo plus AAP in patients with metastatic castration sensitive prostate cancer (mCSPC) and homologous recombinant repair (HRR) gene mutations.1 The data, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in...
FDA approves darolutamide for metastatic castration-sensitive prostate cancer

3 weeks ago | urologytimes.com | Hannah Clarke

The FDA has approved darolutamide (Nubeqa) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), the agency announced in a news release.1Darolutamide was previously approved in the US for the treatment of adult patients with mCSPC in combination with docetaxel, as well as for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.